Citations

Clear

3057 citation(s) found for "Cd, Johnson".

EXTH-37. FUNCTIONAL GENOMICS IDENTIFIES THERAPEUTIC VULNERABILITIES OF GLIOMA SUBTYPES AND YAP/TAZ-ENRICHED TUMORS
Lin, Wan‐Hsin , Kosari, Farhad , Smadbeck, James B. , Barrett, Michael T. , Feathers, Ryan W. , Penheiter, Alan R. , Lynch, Jamie, Sadeghian, Dorsay, Maruthi, Vijaya Kadam, Johnson, Sarah H. , Karagouga, Giannoula, Harris, Faye R. , Berry, T. Dennis, McCune, Alexa, Kinsella, Lindsey, Yang, Lin , Emanuel, Angela, Salvatori, Rebecca , Klein, Janet Schaefer, Ida, Cristine, Jentoft, Mark E. , Sherman, Wendy, Porter, Alyx B. , Rosenfeld, Steven S. , Kizilbash, Sani H. , Jaeckle, Kurt A. , Mrugała, Maciej M. , Quiñones‐Hinojosa, Alfredo , Cheville, John C. , Vasmatzis, George , Anastasiadis, Panos Z. , Kizilbash, Sani H , Sotiriou, Sotiris , Berry, Taylor, Murphy, Stephen J. , Moniz‐Garcia, Diogo , Ensign, Shannon P. Fortin , Salomao, Marcela , Mansfield, Aaron S. , Borad, Mitesh J. , Bendok, Bernard R. , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v232-v232

10.1093/neuonc/noad179.0890 Get It

Abstract Sequencing efforts have identified key oncogenic drivers and transcriptomic subtypes of high-grade gliomas (HGGs), but this knowledge has not resulted in individualized therapy or improved patient outcomes. Here, we used a functional genomics approach combining integrated genomic/transcriptomic analyses with patient-derived 3D micro-cancers (mCancers) to rapidly identify individualized therapeutic vulnerabilities and determine predictive response biomarkers. 30 primary/recurrent HGGs, including 20 glioblastomas, 5 astrocytomas, and 5 oligodendrogliomas, were included for drug testing. mCancers recapitulated the structural and molecular alterations, cellularity, and heterogeneity, of parental patient tumors. A total of 119 single-agent drugs and 183 drug combinations were tested, while a pre-selected drug panel comprising 25 glioma-relevant treatment strategies was tested across all cases. In general, mCancer efficacy corresponded well to historical responses to previously tested agents (EGFR, HDAC inhibitors, etc.). Combined, strong efficacy (i.e. >70% growth inhibition at Cmax) of single treatments targeting deregulated receptor tyrosine kinase (RTK), p53/apoptosis, cell cycle, DNA damage repair, IDH, or telomere maintainance pathways, was observed in 14 out of 30 cases. Surprisingly, transcriptional signatures, but not specific genetic alterations, were found to stratify drug responses. For example, mCancers enriched for the most aggressive mesenchymal (MES) and glycolytic/plurimetabolic (GPM) transcriptional subtypes exhibited stronger response to the BET inhibitor JQ1 (and other clinical BET inhibitors) and the DNA-PKcs/mTOR dual inhibitor CC-115. This therapeutic vulnerability was associated with enrichment of YAP/TAZ signaling, and the glioblastoma stem cell G-STEM signature. Notably, individual combination strategies were effective across tumors, with strong responses ranging from 38% to 77% of all tumors tested. Overall, this study underscores the value of functional genomics in identifying novel vulnerabilities of HGGs and associated response biomarkers. It also highlights the need for further clinical validation of several novel therapies and especially drug combination strategies with strong efficacy in the ex vivo setting.
EXTH-77. EXTENDED HALF-LIFE IL-2 SYNERGIZES WITH Α-PD-1 FOR TREATMENT OF PRECLINICAL MURINE GLIOBLASTOMA MODELS
Tritz, Zachariah P. , Wolf, Delaney, Johnson, Aaron J. , Campian, Jian , Malo, Courtney S. , Yokanovich, Lila T. , Wang, Chensu , Vile, Richard G. , Mercano, Rosa, Wittrup, Dane, Maynes, Mark , Owens, Carley A. , Ayasoufi, Katayoun , Wolf, Delaney M. , Parney, Ian F. , Hanson, Michael, Jin, Fang , Johnson, Aaron J. , Fain, Cori E. , Himes, Benjamin , Goddery, Emma N. , Moynihan, Kelly D , Irvine, Darrell J , Maynes, Mark A

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v242-v242

10.1093/neuonc/noad179.0930 Get It

Abstract α-PD-1 checkpoint blockade is a promising immunotherapeutic approach for many solid tumors; however, this strategy is minimally effective for GBM patients as a monotherapy. One potential reason why α-PD-1 checkpoint blockade is ineffective is the tumor microenvironment and systemic derangements of the immune system which are prevalent in GBM patients. We have successfully modeled peripheral immune derangements in experimental murine GBM models. These include low peripheral blood CD4 T cell counts, reduced MHC class II expression on monocytes, and atrophy of primary immune organs in animals harboring gliomas. We therefore hypothesized that extended half-life IL-2, a potent cytokine which promotes the proliferation, differentiation, and killing activity of T cells, could overcome immune derangements and could potentially synergize with α-PD-1 checkpoint blockade therapy. In cohorts of C57Bl/6 mice, we supplemented α-PD-1 checkpoint blockade with multiple bio-engineered extended half-life IL-2 molecules to treat GL261 and CT2A orthotopic glioma models which are normally resistant to monotherapy. We observe a statistically significant increase in survival in GL261-bearing animals receiving the combination of extended half-life IL-2 reagents and αPD-1 therapy relative to control-treated mice. Some animals receiving this combination therapy had a reduction in tumor burden to levels below detection. These long-term survivors underwent a rechallenge experiment with a second inoculation of GL261-Luc and effectively cleared tumor without further therapeutic intervention. This intervention causes a significant shift in the immune profile, including the formation of mature T cell responses, as well as restoring the diminished peripheral immune cell counts in GL261-bearing animals. Finally, combining extended half-life IL-2 with α-PD-1 checkpoint blockade is effective independently of the CD8 T cell response. Together, these data suggest that combination immunotherapies employing extended half-life IL-2 fusion proteins are translational to the clinic and do not require the identification of tumor specific antigens for efficacy
IMMU-44. CIRCULATING CELL-FREE DNA DIRECTLY INHIBITS T CELL FUNCTION AND CONTRIBUTES TO PERIPHERAL IMMUNOSUPPRESSION IN EXPERIMENTAL GBM
Wolf, Delaney, Reesman, Rachael , Rangel, Frances A., Gulbicki, Lauren , Tritz, Zachariah P. , Hansen, Michael, Johnson, Aaron J. , Ayasoufi, Katayoun , Wolf, Delaney M. , Jin, Fang , Fain, Cori E. , Pfaller, Christian K. , Johnson, Aaron J.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v152-v152

10.1093/neuonc/noad179.0576 Get It

Abstract Glioblastoma (GBM) is aggressive form of brain cancer that is associated with severe peripheral immunosuppression. This immunosuppression is a critical barrier to patient survival and the success of immunotherapies. Immunocompetent mice harboring intracranial gliomas present with the hallmark features of peripheral immunosuppression observed in GBM patients, including T cell lymphopenia. Using parabiosis, we determined that T cell lymphopenia can be transferred from glioma-bearing to healthy mice via circulation This led to the identification of a high molecular weight immunosuppressive factor in sera of glioma-bearing mice that inhibits T cell proliferation ex vivo. Proteomics analysis identified 119 proteins uniquely upregulated in the sera of glioma-bearing mice compared to controls. These proteins are associated with pathways involved in DNA response elements, cell death, and DNA-histone complexes which imply DNA release. Additional analysis revealed serum isolated from glioma-bearing mice harbor significantly higher concentrations of double stranded cell free DNA (cfDNA) compared to controls. Reducing DNA content using DNase partially reverses the proliferation defects observed in T cells when exposed to serum of glioma-bearing mice. This is while, addition of cfDNA purified from serum of glioma-bearing mice, but not genomic DNA, potently inhibited T cell function. These results were AIM2 independent implicating a novel pathway of cfDNA sensing in T cells. We contend that cfDNA induces immunosuppressive effects in experimental GBM. Devising strategies to reduce circulating cfDNA is therefore a therapeutic approach that could improve outcomes in GBM patients.
EPCO-22. LONGITUDINAL MOLECULAR CHARACTERIZATION IDENTIFIES TREATMENT DRIVEN EVOLUTION OF OLIGODENDROGLIOMA
Heo, Chaewon, Ghospurkar, Padmaja L. , Wade, Taylor , Costello, J , Elliott, Carol, Hermes, Beth, Hong, Chibo, Li, Kay Ka‐Wai , Lowman, Allison , McCortney, Katy, Moon, Hyo-Eun, Paek, Sun Ha , Westcott, Kerryn T., Verhaak, Roel G.W. , Chowdhury, Tamrin , Johnson, Kevin C. , Kocakavuk, Emre , Ye, Gordon Y. , Barnholtz‐Sloan, Jill S. , French, Pim J. , Golebiewska, Anna , Horbinski, Craig , Khasraw, Mustafa , LaViolette, Peter S , Lipp, Eric , McCortney, Katy, Ng, Ho‐Keung , Padovan, Marta , Vallentgoed, Wies , Vaubel, Rachael A. , Wesseling, Pieter , Varn, Frederick S.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v128-v128

10.1093/neuonc/noad179.0485 Get It

Abstract Oligodendroglioma is characterized by oligodendrocyte-like histology, mutation in the IDH genes, along with codeletion of chromosome arms 1p and 19q. Treatment for oligodendrogliomas combines surgery, followed by observation, and chemotherapy and/or radiotherapy when tumors progress. Most oligodendrogliomas eventually recur with a more aggressive phenotype, leading to patient mortality but molecular mechanisms remain poorly understood. To investigate the molecular trajectory of oligodendroglioma, we collected more than 270 longitudinal samples from over 130 oligodendroglioma patients, to perform whole genome or whole exome sequencing, bulk RNA, and single-nucleus RNA sequencing (n = 30 samples). Common mutations in IDH1/2, TERT promoter, CIC, and FUBP1 were observed. About half of the CIC and FUBP1 mutations occurred in the initial sample and persisted stably throughout recurrence. The majority of PIK3CA and PIK3R1 mutations were either shared or present in recurrences only implicating the PI3K pathway in oligodendroglioma recurrence. Mutational signature analysis revealed 34.5% of tumors treated with alkylating agents acquired SBS11/SBS31 associated hypermutation. By integrating signatures with clonality estimates, we approximated the timing of mutational processes and found that clonal timings of treatment related mutations correlate with the treatment administration date. We found that aging signature-related mutations were mostly clonal, and treatment signature-related mutations were more likely to be sub-clonal, supporting the late emergence of these mutations following treatment. We observed increased somatic copy number alterations in oligodendroglioma recurrences, reflected in notable chromosome 4 losses. Associating treatment with snRNAseq derived cellular states, we observed a significant increase in the fraction of proliferating stem-like cells in the hypermutator versus non-hypermutator recurrent samples. These findings shed light on the molecular changes occurring in oligodendrogliomas following treatment and provide insights that may aid in targeting treatment resistance.
Implementing artificial intelligence-based cardio-obstetric screening in a diverse patient population: a prospective study
Morales-Lara, Andrea Carolina , Hardway, Heather D , Young, Kendra A. , Douglass, Erika J. , Tobah, Yvonne S. Butler, Rose, Carl H., Burnette, D P, Friedman, Paul A. , Carter, R E, Adedinsewo, Demilade , Hardway, Heather , Johnson, Patrick W. , Young, K A, Tobah, Yvonne Butler , Burnette, David , Attia, Zachi I. , López-Jiménez, Francisco , Noseworthy, Peter A.

Mayo Clinic

European Heart Journal | November 11, 2023 | Volume: 44 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehad655.2730 Get It

Abstract Background Cardiomyopathy is a leading cause of pregnancy-related mortality and represents the number one cause of death in the late postpartum period. Purpose The goal of this study was to prospectively evaluate the effectiveness of an artificial intelligence-based electrocardiogram (AI-ECG) and a point-of-care artificial intelligence-enhanced digital stethoscope for cardiomyopathy screening among pregnant and postpartum women. Methods We conducted a single-arm prospective study of pregnant and postpartum women (up to 12 months following delivery) enrolled at three sites between October 2021 and October 2022. Study participants completed a standard 12-lead ECG, ECG + phonocardiogram recordings with a digital stethoscope, a demographic questionnaire, and a transthoracic echocardiogram (TTE) within a 24-hour period. Diagnostic performance of the AI-ECG and digital stethoscope for cardiomyopathy detection, defined as left ventricular ejection fraction (LVEF) < 45%, was evaluated using the area under the curve (AUC) and standard measures of diagnostic performance. Results We included 100 consecutive pregnant and postpartum women who provided informed consent and had at least one ECG recorded, completed the questionnaire, and had an echocardiogram performed. All participants self-identified as female, and 41% were recruited from a federally qualified health center. The median age of participants was 31 years (Q1: 27, Q3: 34). Thirty-eight percent identified as non-Hispanic White, 32% as non-Hispanic Black, 21% as Hispanic or Latino, 6% as Asian, and 3% as Other (1 Native Hawaiian and 2 multiracial). Five percent (5/100) had LVEF <45%. The 12-lead AI-ECG model demonstrated close to perfect discrimination (accuracy 99%; AUC 1.00, sensitivity 100%) for detection of cardiomyopathy with 1 false positive screen (LVEF 49%), Figure 1A. The digital stethoscope (angled position) had an AUC of 0.99 (95% CI: 0.97, 1.00) for detection of LVEF <45%. Sensitivity, specificity, positive predictive value, and negative predictive value for the digital stethoscope were 60%, 98%, 60% and 98%, respectively for detection of LVEF <45% (Figure 1B & 1C). Conclusions In this small prospective study, we found that 5% of pregnant and postpartum women had cardiomyopathy, a potentially life-threatening condition, and that a rapid, inexpensive, ubiquitous, massively scalable point-of-care test - the ECG - showed promising results, identifying it with an AUC > 0.98 with the application of artificial intelligence.Figure 1
Correction: Joseph et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals 2023, 16, 1164
Núñez, Nicolás A. , Kung, Simon , Voort, Jennifer L. Vande , Schak, Kathryn M. , Boehm, Stacey M., Carpenter, Brooke, Johnson, Emily K. , Malyshev, Grigoriy, Smits, Nathan , Adewunmi, Daniel O., Brown, Sarah K , Singh, Balwinder , Joseph, Boney , Vande Voort, Jennifer L , Singh, Balwinder , Joseph, Boney , Pazdernik, Vanessa , Smits, Nathan

Mayo Clinic

Pharmaceuticals | November 7, 2023 | Volume: 16 | Issue: 11 | Pages: 1571

10.3390/ph16111571 | PMID 38004498 Get It

In the original publication [...]
TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas
Zheng, Jiaying , Wang, Lingxiao , Bosco, Dale B. , Huang, Tao , Dheer, Aastha , Gao, Shan , Xu, Shengze , Ayasoufi, Katayoun , Al‐kharboosh, Rawan , Johnson, Aaron J. , Quiñones‐Hinojosa, Alfredo , Wu, Long‐Jun , Chang, Yuzhou, Ayasoufi, Katayoun , Al-Kharboosh, Rawan, Wu, Long-Jun , Zheng, Jiaying , Zhao, Shunyi , Zhang, Wenjing, Chang, Yuzhou , Qi, Fangfang , Xie, Manling , Johnson, Aaron J. , Dong, Haidong

Mayo Clinic

Neuro-Oncology | November 3, 2023 | Volume: 26 | Issue: 5 | Pages: 811-825

10.1093/neuonc/noad214 | PMID 37941134 Get It

Abstract Background Myeloid cells comprise up to 50% of the total tumor mass in glioblastoma (GBM) and have been implicated in promoting tumor progression and immunosuppression. Modulating the response of myeloid cells to the tumor has emerged as a promising new approach for cancer treatment. In this regard, we focus on the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), which has recently emerged as a novel immune modulator in peripheral tumors. Methods We studied the TREM2 expression profile in various patient tumor samples and conducted single-cell transcriptomic analysis in both GBM patients and the GL261 mouse glioma model. We utilized multiple mouse glioma models and employed state-of-the-art techniques such as invivo 2-photon imaging, spectrum flow cytometry, and in vitro co-culture assays to study TREM2 function in myeloid cell-mediated phagocytosis of tumor cells, antigen presentation, and response of CD4+ T cells within the tumor hemispheres. Results Our research revealed significantly elevated levels of TREM2 expression in brain tumors compared to other types of tumors in patients. TREM2 was predominantly localized in tumor-associated myeloid cells and was highly expressed in nearly all microglia, as well as various subtypes of macrophages. Surprisingly, in preclinical glioma models, TREM2 deficiency did not confer a beneficial effect; instead, it accelerated glioma progression. Through detailed investigations, we determined that TREM2 deficiency impaired the ability of tumor-myeloid cells to phagocytose tumor cells and led to reduced expression of MHCII. This deficiency further significantly decreased the presence of CD4+ T cells within the tumor hemispheres. Conclusions Our study unveiled a previously unrecognized protective role of tumor-myeloid TREM2. Specifically, we found that TREM2 enhances the phagocytosis of tumor cells and promotes an immune response by facilitating MHCII-associated CD4+ T-cell responses against gliomas.
Pemphigoid gestationis and polymorphic eruption of pregnancy: treatment and outcomes in a retrospective cohort study
Xie, Fangyi , Lehman, Julia S. , Baban, Farah , Johnson, Emma F. , Theiler, Regan N. , Todd, Austin, Lehman, Julia S , Theiler, Regan , Davis, Dawn Marie R.

Mayo Clinic

International Journal of Dermatology | November 2, 2023 | Volume: 63 | Issue: 1 | Pages: No page available

10.1111/ijd.16884 | PMID 37916499 Get It

Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis
Mahmoud, Ahmed , Childs, Daniel S. , Ahmed, Mohamed E. , Johnson, Geoffrey B. , Orme, Jacob J. , Stish, Bradley J. , Phillips, Ryan , Andrews, Jack R. , Kwon, Eugene D., Mahmoud, Ahmed M , Phillips, Ryan M., Davis, Brian J. , Andrews, Jack R , Childs, Daniel S , Johnson, Geoffrey B , Ahmed, Mohamed , Kendi, A. Tuba , Park, Sean S.

Mayo Clinic

The Prostate | October 30, 2023 | Volume: 84 | Issue: 3 | Pages: 237-244

10.1002/pros.24643 | PMID 37899635 Get It

AbstractBackgroundProstate cancer (PCa) parenchymal brain metastases are uncommon and troubling observations in the course of the disease. Our study aims to evaluate the prevalence of brain metastases among PCa patients while reporting various therapeutic modalities, clinical features, and oncological outcomes.MethodsWe retrospectively identified 34 patients with parenchymal brain metastasis out of 4575 patients using a prospectively maintained database that contains clinicopathologic characteristics of PCa patients between January 2012 and December 2021. Based on the three treatment modalities used, the patients were divided into three groups: stereotactic radiosurgery (SRS), whole brain radiotherapy (WBRT), and systemic therapy alone. The Kaplan–Meier curve was used to calculate overall survival [OS] probability and the Cox proportional hazards regression model was used to compare between groups.ResultsAt the time of brain metastasis diagnosis, the median age was 66 years, the median (interquartile range [IQR]) prostate‐specific antigen (PSA) was 2.2 (0.1–26.6) ng/ml and the median (IQR) months from initial PCa diagnosis to brain metastasis development was 70.8 (27.6–100.9). The median (IQR) primary Gleason score was 8 (7–9) and over a median (IQR) follow‐up time of 2.2 (1.2–16.5) months, 76.5% (n = 26) of the patients died. Thirteen (38.2%) patients had solitary lesion, whereas 21 (61.8%) had ≥2 lesions. The lesions were supratentorial in 19 (55.9%) patients, infratentorial in six (17.6%), and both sides in nine (26.5%). Among all 34 patients, 10 (29.4%) were treated with SRS, seven (20.6%) with WBRT, and 17 (50%) with systemic therapy alone. OS varied greatly between the three treatment modalities (log‐rank test, p = 0.049). Those who were treated with SRS and WBRT had better OS compared with patients who were treated with systemic therapy alone (hazard ratio: 0.37, 95% confidence interval: 0.16–0.86, p = 0.022).ConclusionsIn our single‐institutional study, we confirmed that PCa brain metastasis is associated with poor survival outcomes and more advanced metastatic disease. Furthermore, we found that SRS and WBRT for brain metastasis in patients with recurrent PCa appear to be associated with improved OS as compared with systemic therapy alone and are likely secondary to selection bias.
A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC
Walsh, Thomas J. , Ahmed, Sarah , Alastruey‐Izquierdo, Ana , Alexander, Barbara D. , Arendrup, Maiken Cavling , Babady, Esther , Balada-Llasat, Joan-Miquel, Borman, Andrew M. , Colgrove, Robert C. , Cornely, Oliver A. , Fuller, Jeff, Gibas, Connie Fe C., Glasgow, Heather, Gräser, Yvonne , Groll, Andreas H. , Haase, Gerhard , Hanson, Kimberly E. , Harrington, Amanda, Hayden, Randall T. , Hubka, Vít , Johnson, Kristie, Li, Ruoyu , Lanternier, Fanny , Leal, Sixto M. , Lee, Francesca , Luethy, Paul M. , Kwon‐Chung, Kyung J., Palavecino, Elizabeth , Pancholi, Preeti , Pappas, Peter G. , Procop, Gary W. , Rhoads, Daniel D. , Riedel, Stefan , Stevens, Bryan S. , Sullivan, Kaede Ota, Vergidis, Paschalis , Roilides, Emmanuel , Seyedmousavi, Amir, Tao, Lili , Vicente, Vânia Aparecida , Vitale, Roxana G. , Wengenack, Nancy L. , Westblade, Lars F. , Wiederhold, Nathan P. , White, Lewis, Wojewoda, Christina , Babady, N. Esther , Seyedmousavi, Seyedmojtaba , de Hoog, Sybren , Walsh, Thomas J , Ahmed, Sarah A , Alastruey-Izquierdo, A , Arendrup, Maiken Cavling , Borman, Andrew , Groll, Andreas H , Hanson, Kimberly , Hayden, Randall T , Hoenigl, Martin , Kus, Julianne V , Meis, Jacques F , Leal, Sixto M , Lockhart, Shawn R. , Luethy, Paul , Kwon-Chung, Kyung J , Nguyen, M Hong , Pancholi, Preeti , Procop, Gary W , Rhoads, Daniel D , Riedel, Stefan , Vergidis, Paschalis , Vitale, Roxana G , Wengenack, Nancy L , White, Lewis , Wojewoda, Christina M , Zhang, Sean X , Cornely, Oliver A , Roilides, Emmanuel , Wiederhold, Nathan , Bai, Feng‐Yan , Chowdhary, Anuradha , Clark, Andrew, Dingle, Tanis C. , Dufresne, Philippe J. , Gangneux, Jean‐Pierre , Guillot, Jacques , Hawksworth, David L. , Hoenigl, Martin , Kus, Julianne V. , Lackner, Michaela , Martin, Isabella W. , Meyer, Wieland , Ostrosky‐Zeichner, Luis , Redhead, Scott A. , Stevens, Bryan, Wang, Qiming , Zhang, Sean X.

Mayo Clinic

Journal of Clinical Microbiology | October 26, 2023 | Volume: 61 | Issue: 11 | Pages: No page available

10.1128/jcm.00873-23 | PMID 37882528 Get It

ABSTRACT The rapid pace of name changes of medically important fungi is creating challenges for clinical laboratories and clinicians involved in patient care. We describe two sources of name change which have different drivers, at the species versus the genus level. Some suggestions are made here to reduce the number of name changes. We urge taxonomists to provide diagnostic markers of taxonomic novelties. Given the instability of phylogenetic trees due to variable taxon sampling, we advocate to maintain genera at the largest possible size. Reporting of identified species in complexes or series should where possible comprise both the name of the overarching species and that of the molecular sibling, often cryptic species. Because the use of different names for the same species will be unavoidable for many years to come, an open access online database of the names of all medically important fungi, with proper nomenclatural designation and synonymy, is essential. We further recommend that while taxonomic discovery continues, the adaptation of new name changes by clinical laboratories and clinicians be reviewed routinely by a standing committee for validation and stability over time, with reference to an open access database, wherein reasons for changes are listed in a transparent way.